Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Title:

Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Dataset

identifier:	1942461
description:	epitope description:DAEFRH antigen name:Amyloid beta A4 protein host organism:Homo sapiens
aggregation:	instance of dataset
availability:	available
primaryPublications:	22677258

Access

authorizations:	registration not required
accessURL:	http://www.iedb.org/reference/1024441
landingPage:	http://www.iedb.org/assay/1942461

Publication

type:	Literature
publicationVenue:	Lancet Neurol
dates:	2012

Dimension

study type:	b cell assays
subject species:	Homo sapiens

Person

fullName:	Bengt Winblad Niels Andreasen Lennart Minthon Annette Floesser Georges Imbert Thomas Dumortier R Paul Maguire Kaj Blennow Joens Lundmark Matthias Staufenbiel Jean-Marc Orgogozo Ana Graf

Data Type

method:	ELISA

Study

name:	Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Data Repository

name:	iedb
homePage:	http://www.iedb.org

Feedback?

If you are having problems using our tools, or if you would just like to send us some feedback, please post your questions on Feedback.